In B-cell lymphoma, EZH2 inhibition can increase the expression of the chemokine C–C motif chemokine ligand 17, induce T-cell chemotaxis, and promote the T-cell-rich tumor microenvironment.107. Here, EZH2 is linked to B-cell non-Hodgkin lymphoma.